Our plans for the next year include: (1) the continuing investigation of tumor-inhibitory and other biological effects of alpha, beta, and lambda interferons in cancer patients; (2) the completion of two clinical trials aimed at defining immunological and tumor inhibitory effects of Thymosin Fraction 5 in cancer patients; (3) the study of conditions that affect the release of tumor necrosis factor, interleukin-1, and leukemia-differentiating protein in cancer patients treated with endotoxin; (4) the dissection of the serological response of renal cancer patients to renal cancer vaccines by autologous typing using the patients' serum as well as monoclonal antibodies produced by their lymphocytes; and (5) the characterization of biological activities, in vitro and in vivo, of mouse monoclonal antibodies with restricted specificity for malignant melanoma, renal cancer, lung cancer, bladder cancer, and colon cancer. (CS)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA036137-02
Application #
3173643
Study Section
Immunobiology Study Section (IMB)
Project Start
1984-07-01
Project End
1987-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065